Heidelberg, Germany, November 28, 2018 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate and adaptive immunity (NK cells, macrophages and T cells), today announced that it will host a Research & Development Day on Friday, December 7, 2018 from 8:30 am to 11:30 am ET in New York City.

In addition to presentations on the Company’s clinical development strategy for its lead product candidate AFM13 and its advanced innate immune cell engager pipeline, the event will feature guest speakers Dr. Steven M. Horwitz, Associate Attending, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, Dr. Yago Nieto, Professor of Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, and Dr. Ahmed Sawas, Assistant Professor of Medicine, Columbia University College of Physicians and Surgeons and the New York-Presbyterian Hospital. The speakers have extensive background in the development of innovative medicines in hematological malignancies including T cell lymphoma and Hodgkin lymphoma.

A live webcast of the full program can be accessed through the “Events” section on the “Investors & Media” page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed’s website for 30 days following the event.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK cells, macrophages and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.

Affimed Media Contact:
Anca Alexandru, Head of Communications, EU IR
E-Mail: [email protected]

Affimed Investor Contact:
Gregory Gin, Head of Investor Relations
E-Mail: [email protected]